Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDICA 16
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MEDICA 16 (3,3,14,14-tetramethylhexadecanedioic acid) is a non-metabolizable long-chain dicarboxylic fatty acid analogue originally developed by researchers at the Hebrew University of Jerusalem as a hypolipidemic, antiobesity, and antidiabetic agent. It acts as a dual inhibitor of ATP-citrate lyase (ACLY) and acetyl-CoA carboxylase (ACC), thereby suppressing de novo lipogenesis and cholesterogenesis. Additionally, MEDICA 16 acts as an agonist of free fatty acid receptor 1 (FFAR1/GPR40) and peroxisome proliferator-activated receptor alpha (PPARα), and functions as a mitochondrial uncoupling agent. Although it demonstrated significant efficacy in improving insulin sensitivity and reducing plasma triglycerides in various rodent models of obesity and insulin resistance, MEDICA 16 did not advance beyond preclinical development.
- Other names
- 3,3,14,14-tetramethylhexadecanedioic acidbeta,beta'-methyl-substituted hexadecanedioic acidbeta,beta'-tetramethylhexadecanedioic acidhexadecanedioic acid, 3,3,14,14-tetramethyl-Medic-16Medic16Medic 16
02
Targets
ACLY (ATP-citrate synthase)ACC (Acetyl-CoA Carboxylase 1)FFAR1 (Free fatty acid receptor 1)ME (Protocadherin beta-11)ANT1/2/3 (Mitochondrial ADP/ATP translocase)GPD2 (Glycerol-3-phosphate dehydrogenase 2)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on MEDICA 16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDICA 16.